French Building Stock News

Germany’s push to reshape its air defence, including the €750b spending plan by 2030 and the new “Team Gen 6” fighter jet alliance, is reshuffling expectations for several European aerospace and defence stocks. Some companies now sit closer to potential long term contracts, while others face questions as older joint projects lose momentum. This article highlights three stocks from a European Defence & Aerospace screener that are closely tied to these developments and appear positively exposed...

Voltalia (ENXTPA:VLTSA) has drawn fresh attention after signing a Transmission System Use Agreement with Brazil’s National Electric System Operator, locking in 322 megawatts of grid capacity at the Pecém Industrial and Port Complex. See our latest analysis for Voltalia. The latest agreement in Brazil comes after a period of mixed trading, with the share price falling 7.7% over the past week but rising 10.1% over 30 days, while the 1 year total shareholder return is down 12.4%. This suggests...

The market was pleased with the recent earnings report from Coheris SA ( EPA:COH ), despite the profit numbers being...

Eurazeo (ENXTPA:RF) has drawn fresh investor attention after closing its seventh direct lending fund at €3.9 billion, above its original €3 billion target, with total programme commitments of €5.5 billion. See our latest analysis for Eurazeo. Despite closing the enlarged direct lending fund, Eurazeo’s share price has been under pressure, with the year to date share price return down 16.78% and the 1 year total shareholder return declining 24.89%. This suggests recent news has not yet shifted...

OPmobility (ENXTPA:OPM) has drawn fresh attention after announcing a new Exterior solutions manufacturing plant in Wood County near Toledo, Ohio, in partnership with state and local authorities. See our latest analysis for OPmobility. Recent trading has been choppy, with the share price at €15.62 after a 1 day share price return of 0.71% and a 7 day share price return that declined 6.07%. However, the 1 year total shareholder return of 48.62% points to stronger momentum over a longer...

Earlier this month, Elis confirmed past Management Board changes, including the future departure of long-serving member Matthieu Lecharny in September 2026 and the appointment of current COO Yann Michel to succeed him for a four-year term, alongside the reappointment of Chairman Xavier Martiré and board member Louis Guyot through 2030. The carefully staged transition, elevating an internal operations leader with deep international experience, signals an emphasis on continuity in executing...

Acquisition push puts Saint-Gobain’s portfolio moves in focus Compagnie de Saint-Gobain (ENXTPA:SGO) used its recent board and shareholders’ meetings to underline a fresh round of acquisition plans, particularly in construction chemicals, alongside ongoing disposals to reshape its business mix. For you as an investor, that means the stock now sits against a backdrop of a €6.5b construction chemicals platform, recent portfolio sales in Brazil and Belgium, and a planned €9b investment program...

Teleperformance (ENXTPA:TEP) has just completed a tender offer for parts of its 2027 and 2028 euro bonds, a refinancing move that reshapes its debt profile and could influence investor views on financial resilience. See our latest analysis for Teleperformance. The share price has come under pressure recently, with a 1 day share price return of 4.79% and a 30 day share price return of 6.71%. The 90 day share price return of 9.79% contrasts with a 1 year total shareholder return decline of...

Renault (ENXTPA:RNO) has recently drawn investor attention after a period of weaker share performance, with the stock down over the past month and past 3 months. This has prompted closer scrutiny of its current valuation. See our latest analysis for Renault. The recent 7 day share price return, down 9.4%, extends a weaker pattern, with the year to date share price return down 26.27% and the 1 year total shareholder return down 32.91%, suggesting momentum has been fading. If this slide has you...

Short term moves versus longer term performance With no specific news event driving headlines today, attention on Amundi (ENXTPA:AMUN) often centers on how its recent share price moves compare with its longer term performance and the fundamentals of its asset management business. The stock is roughly flat over the past month but higher over the past 3 months, alongside a 1-year total return of 21.8% and a 3-year total return that is a very large multiple of the starting point. Over 5 years,...

Recent performance snapshot and what it may mean for investors Without a single defining news event driving headlines, Rémy Cointreau (ENXTPA:RCO) has still given investors plenty to consider, with mixed short term and longer term share performance across different timeframes. The stock is up about 1.5% over the past day and 4.6% over the past week. Moves over the past month and past 3 months sit around flat and 10% respectively, which may point to shifting sentiment. See our latest analysis...

Why this board change matters for Forvia investors Forvia (ENXTPA:FRVIA) drew fresh attention after its June 4 combined general meeting, where Pierre-André de Chalendar joined the Board for four years and was immediately elected Chairman following Michel de Rosen’s resignation. Alongside this leadership transition, the company also recently reported its total voting rights and share count as of May 31, 2026, giving investors an up to date view of ownership structure and governance. See our...

Shareholders might have noticed that Wavestone SA ( EPA:WAVE ) filed its yearly result this time last week. The early...

SCOR (ENXTPA:SCR) has drawn fresh attention after first quarter results exceeded analyst expectations on non life underwriting, helped by relatively low catastrophe claims, even as renewal premiums declined across several reinsurance lines. See our latest analysis for SCOR. SCOR’s first quarter underwriting surprise has come alongside relatively steady share price momentum, with the 90 day share price return of 3.60% and year to date share price return of 8.30%. The 5 year total shareholder...

Why Société BIC (ENXTPA:BB) is on investors’ radar Société BIC (ENXTPA:BB) has drawn attention after recent share price moves, with the stock last closing at €55.50 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Société BIC. At €55.50, Société BIC’s recent share price pullback over the past week and month sits against a year to date share price return of 7.56% and a 1 year total shareholder return of 5.04%. This suggests momentum has cooled...

Eiffage (ENXTPA:FGR) stock has been reacting to fresh contract wins after Campus AI selected the group to build a high voltage substation at its Fouju campus, alongside a separate bridge replacement project in Nuremberg. See our latest analysis for Eiffage. At a share price of €124.95, Eiffage’s stock has inched higher over the year to date, with a 1-year total shareholder return of 8.14% and a 5-year total shareholder return of 66.38%. However, the 30-day share price return declined 12.44%,...

Exail Technologies (ENXTPA:EXA) is back in focus after fresh financials showed Q1 2026 revenue of €131 million versus €94 million a year earlier, along with an updated discounted cash flow analysis flagging potential undervaluation. See our latest analysis for Exail Technologies. The latest move in Exail Technologies' share price has been choppy, with the stock down 1.49% over the last day and 8.28% over the past week, yet still showing a 54.88% year to date share price return and a very...

Wondering if BNP Paribas at €93.65 is still offering value or if most of the easy gains are already behind it? This article walks through the numbers so you can judge for yourself. The stock has returned 0.8% over the last week, 0.3% over the last month, 14.3% year to date and 27.6% over the past year, with longer term returns of 102.0% over three years and 137.4% over five years putting recent moves into context. Recent coverage of BNP Paribas in broader market commentary has focused on how...

TotalEnergies (ENXTPA:TTE) has received Russian approval to exit the U.S. sanctioned Arctic LNG 2 project, unwinding its 10% stake. Seven U.S. states have launched legal action over a Trump era agreement tied to the company’s withdrawal from new offshore wind projects in the U.S. Both developments center on long term energy policy, sanctions, and the balance between fossil fuels and renewables in TotalEnergies’ portfolio. TotalEnergies is a large integrated energy company with oil, gas, and...

Multiple class action lawsuits targeting CeraVe acne products have thrust L'Oréal (ENXTPA:OR) into the spotlight, prompting investors to reassess product safety risks, potential legal liabilities, and how these might influence sentiment toward the stock. See our latest analysis for L'Oréal. Recent share price moves suggest sentiment is steady rather than surging, with a 1-day share price return of 1.24% and a 1-year total shareholder return of 0.40%. Multi year total shareholder returns...

In recent months, HM Revenue & Customs announced a multi-year agreement with Capgemini, NiCE and Route 101 to modernise its customer service systems and expand digital self-service and AI-enabled support for UK taxpayers. This win underscores Capgemini’s growing role as a core digital transformation partner for large public-sector clients, especially in cloud, data and AI-led service delivery. Next, we’ll examine how this HMRC customer-service modernisation contract could influence...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Edenred SE ( EPA:EDEN ) is about to trade ex-dividend in the next three days. Typically, the ex-dividend date is two...

In May 2026, Ipsen reported new late-breaking Phase III and real-world data at the European Association for the Study of the Liver congress showing IQIRVO improved fatigue, pruritus and key biochemical markers in primary biliary cholangitis, with a tolerability profile consistent with earlier studies. The results further underline IQIRVO’s role as a differentiated second-line option in PBC, backed by both controlled trials and real-world evidence across multiple countries. We’ll now examine...